Charles_Sawyers

Charles Sawyers

Charles Sawyers

American physician-scientist (born 1959)

Charles L. Sawyers (born 1959) is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.[2]

Quick Facts Born, Education ...

Career

Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985,[3] followed by an internal medicine residency at the University of California, San Francisco.[4] He became a HHMI investigator in 2002 while working at UCLA's Jonsson Cancer Center.[5]

Sawyers works on molecularly targeted cancer drugs, with a focus on developing a new generation of treatment options for patients. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award with Brian J. Druker and Nicholas Lydon,[6] for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance. He also co-discovered the antiandrogen drugs enzalutamide, approved by the FDA in 2012, and apalutamide[7] approved in 2019, both for treatment of advanced prostate cancer.[8]

Sawyers' cancer research is discussed in the second episode of Cancer: The Emperor of All Maladies.

Significant positions

Sawyers served as president of the American Society for Clinical Investigation (ASCI) in 2007[9] and of the American Association for Cancer Research (AACR) in 2012.[10] He was also appointed to the National Cancer Advisory Board by President Obama in 2012,[11] and has served on the Board of Directors of Novartis since 2013.[12] He was a founding co-editor of the Annual Review of Cancer Biology in 2017,[13] serving until 2021.[14]

Memberships

Awards

References

  1. [1]
    Howard Hughes Medical Institute, Annual Scientific Report, The Institute, 1990, p. 507.
  2. [2]
    "At Work: Human Oncology and Pathogenesis Program Chair Charles Sawyers | Memorial Sloan Kettering Cancer Center". www.mskcc.org. Retrieved 5 April 2017.
  3. [3]
    "Susan Schneck Weds Charles Sawyers". The New York Times. 22 October 1990. Retrieved 3 March 2017.
  4. [4]
    "UCSF Department of Medicine Alumni Profile: Dr. Charles Sawyers". medicine.ucsf.edu. Archived from the original on 8 September 2015. Retrieved 3 March 2017.
  5. [5]
    "Charles L. Sawyers, MD". HHMI.org. Retrieved 5 April 2017.
  6. [6]
    Grindlinger, Brooke; Chao, ES (1 October 2009). "Trio receives Lasker Foundation Clinical Award for breakthroughs in leukemia treatment". Journal of Clinical Investigation. 119 (10): 2863–2865. doi:10.1172/JCI41141. ISSN 0021-9738. PMC 2752112.
  7. [7]
    Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL (2009). "Development of a second-generation antiandrogen for treatment of advanced prostate cancer". Science. 324 (5928): 787–90. Bibcode:2009Sci...324..787T. doi:10.1126/science.1168175. PMC 2981508. PMID 19359544.
  8. [8]
    Reyes, Antonio A.; Akeson, Richard (1988). "Generation of Multiple Independent Substitution Mutants by M13 in Vitro Mutagenesis Using a Single Mutagenic Oligonucleotide". DNA. 7 (8): 579–584. doi:10.1089/dna.1.1988.7.579. PMID 3180999.
  9. [9]
    "2008 American Society for Clinical Investigation Presidential Address" (PDF). the-asci.org. Retrieved 3 March 2017.
  10. [10]
    "Charles L. Sawyers, MD". aacr.org. Retrieved 4 March 2017.
  11. [11]
    "President Obama Announces More Key Administration Posts". whitehouse.gov. 6 December 2012. Retrieved 4 March 2017.
  12. [12]
    "Charles L. Sawyers, M.D. Member of the Board of Directors" (PDF). novartis.com. Retrieved 4 March 2017.
  13. [13]
    Jacks, Tyler; Sawyers, Charles (2017). "Introduction". Annual Review of Cancer Biology. 1: i. doi:10.1146/annurev-ca-01-121516-100001.
  14. [14]
    "Annual Review of Cancer Biology Editorial Committee". Annual Reviews. 2022. Retrieved 18 July 2022.
  15. [15]
    "Doris Duke Charitable Foundation Awards $10.5 Million for Medical Research". Philanthropy News Digest (PND). Retrieved 5 April 2017.
  16. [16]
    "Recipients of the David A. Karnofsky Memorial Award and Lecture - The ASCO Post". www.ascopost.com. Archived from the original on 19 September 2017. Retrieved 5 April 2017.
  17. [17]
    "Awards, Appointments, Announcements". JNCI Journal of the National Cancer Institute. 97 (11): 797. 1 June 2005. doi:10.1093/jnci/97.11.797.
  18. [18]
    "Dorothy P. Landon-AACR Prize for Translational Cancer Research". www.aacr.org. Archived from the original on 3 September 2017. Retrieved 5 April 2017.
  19. [19]
    Foundation, Lasker. "Molecularly targeted treatments for chronic myeloid leukemia | The Lasker Foundation". The Lasker Foundation. Retrieved 5 April 2017.
  20. [20]
    "Breakthrough Prize". breakthroughprize.org. Retrieved 5 April 2017.
  21. [21]
    "Taubman Prize". A. Alfred Taubman Medical Research Institute. Retrieved 16 March 2017.
  22. [22]
    "2014 Honorees". The Hope Funds for Cancer Research. 5 September 2013. Retrieved 5 April 2017.
  23. [23]
    "BBVA Foundation Frontiers of Knowledge Awards". www.fbbva.es. Archived from the original on 21 September 2015. Retrieved 5 April 2017.
Share this article:

This article uses material from the Wikipedia article Charles_Sawyers, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.